10x Genomics Inc

Latest Results (13.10.2025):

10x Genomics Inc reported its financial results for the second quarter of 2025, demonstrating a resilient performance amidst a challenging funding environment. The company achieved a revenue of $172.9 million, with core revenue excluding a patent litigation settlement totaling $145.6 million. Notably, 10x Genomics reported a net income of $34.5 million, a significant turnaround from a net loss in the same quarter last year.

Revenue Performance

For Q2 2025, 10x Genomics reported total revenue of $172.9 million. Excluding a $27.3 million patent litigation settlement, the core revenue was $145.6 million, marking a 5% decrease compared to Q2 2024, primarily due to a decline in instrument sales.

Gross Margin Improvement

The company's gross margin increased to 72% in Q2 2025 from 68% in the prior year. This improvement was driven by higher license and royalty revenues and lower royalties and warranty costs.

Operating Expenses Reduction

Operating expenses for the second quarter decreased by 35% to $95.0 million from $146.0 million in Q2 2024, largely due to a $40.7 million gain from the litigation settlement.

Operating Income Turnaround

10x Genomics achieved an operating income of $30.1 million in Q2 2025, a significant improvement from an operating loss of $41.7 million in the same period last year.

Net Income Achievement

The company reported a net income of $34.5 million for the second quarter of 2025, reversing the net loss of $37.9 million recorded in Q2 2024.

Cash Position Strengthens

As of June 30, 2025, 10x Genomics held $447.3 million in cash, cash equivalents, and marketable securities, reflecting a $20 million increase from the previous quarter.

Strategic Acquisition

10x Genomics entered into an agreement to acquire Scale Biosciences for $30 million in upfront cash and stock, enhancing its capabilities in single cell analysis and expanding its technological leadership.

Product Portfolio Expansion

The company began shipping Visium HD 3’ and HD cell segmentation, broadening the Visium portfolio’s capabilities for high-resolution and high-sensitivity profiling across diverse applications.

Key Partnerships

10x Genomics announced a partnership with the Genome Institute of Singapore on the TISHUMAP initiative, leveraging Xenium and AI technologies to discover novel biomarkers and therapeutic targets for cancer and inflammatory diseases.

Future Revenue Guidance

For the third quarter of 2025, 10x Genomics expects revenue to range between $140 million and $144 million, factoring in accelerated purchases from Chinese customers anticipating tariff changes.